Expert Point of View: Louis M. Weiner, MD


Get Permission

Commenting on both Dr. Baselga’s study in breast cancer and Dr. Liu’s study in ovarian cancer at the AACR press conference, Louis M. Weiner, MD, Director of the Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC, said that antibody-drug conjugates “represent the fulfillment of the century-long dream of Paul Ehrlich—that of magic bullets for the treatment of cancer.”

“One of the main takeaway messages from Dr. Baselga’s study is that biomarkers no longer matter when you have drugs that work very well and overcome defense mechanisms of the tumor,” Dr. Weiner said.

The lessons of T-DM1 are not unique to that agent, but apply to other antibody-drug conjugates as well. “The therapeutic concept of antibody-drug conjugates makes sense. Target the antigen on the cell surface, and deliver powerful cytotoxic chemotherapy. The antibody delivers the potent drug that could not be given otherwise to exactly where it needs to go,” he elaborated. “This is where the field is heading for novel cytotoxics.” ■

Disclosure: Dr. Weiner reported no potential conflicts of interest.


Related Articles

Higher HER2 Expression Linked to Best Results with T-DM1 in Patients with HER2-positive Metastatic Breast Cancer

A biomarker analysis of the pivotal EMILIA trial suggests that women with metastatic HER2-positive breast cancer with tumors that have high expression of HER2 derive the most robust benefit from treatment with the antibody-drug conjugate T-DM1 (also now known as ado-trastuzumab emtansine...

SIDEBAR: First Report of Antibody-Drug Conjugate in Advanced Ovarian Cancer

In a related presentation at the AACR Annual Meeting,1 the antibody-drug conjugate DMUC5754A showed encouraging activity in women with ovarian cancer, particularly those with platinum-resistant disease, which currently lacks effective treatment options. The first-in-human phase I study included 44...


Advertisement

Advertisement



Advertisement